Abstract:Clinical trials have demonstrated that concurrent administration of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) with chemotherapy agents does not improve overall survival in patients with non-small-cell lung cancer. Autophagy might play an important role in the resistance to EGFR-TKIs and/or chemotherapy agents. In the present study, we found that a combination of gefitinib and cisplatin generated antagonistic effects in EGFR-TKI-sensitive cells and that previously inhibiting autophagy by chloroquine could produce synergistic effect by increasing apoptosis.Background: Four large clinical trials have shown that concurrent administration of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), such as gefitinib or erlotinib, with chemotherapy agents does not improve overall survival (OS) in unselected patients with advanced non-small-cell lung cancer (NSCLC). In the present study, the role of autophagy in the combination of gefitinib and cisplatin on EGFR-TKI-sensitive human lung cancer cell line was investigated. Moreover, whether simultaneous autophagy inhibition treatment increases the antitumor activity was explored. Materials and Methods: The PC9 cell was exposed to either gefitinib or cisplatin alone or together. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cytotoxic interaction between gefitinib and cisplatin was determined using coefficient of drug interaction (CDI) analysis. The cell cycle distribution and apoptosis were measured using flow cytometry. Alterations in the autophagy and apoptosis signaling pathway were measured using Western blot assays. Results: Coadministration of gefitinib and cisplatin resulted in antagonistic activity to tumor cell proliferation. However, the addition of chloroquine (CQ), an autophagy inhibitor, overcame the antagonistic effects, as demonstrated by CDI analysis and Annexin V-FITC/propidium iodide (PI) assays. In addition, gefitinib administration led to cell G1 phase arrest, which might have contributed to the antagonistic activity between gefitinib and cisplatin. However, the addition of CQ did not deregulate cell cycle arrest, indicating that other mechanisms might be involved. The Annexin V-FITC/PI assays showed that the addition of CQ significantly the increased the ratio of apoptosis cells. Also, immunoblotting assays exhibited increased Bax and decreased Bcl-2, suggesting that autophagy inhibition by CQ could increase cell apoptosis and thus overcome the antagonistic effects. Conclusion: The combination of gefitinib with cisplatin generates antagonistic effects on EGFR-TKI-sensitive cells. However, inhibiting autophagy produces a synergistic effect, suggesting that gefitinib and cisplatin combined with an autophagy inhibitor (especially CQ) might be a beneficial strategy to overcome the antagonistic effects between EGFR-TKIs and chemotherapeutic agents. (C) 2015 Elsevier Inc. All rights reserved.

Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

EGFR Tyrosine Kinase Inhibitors Activate Autophagy As a Cytoprotective Response in Human Lung Cancer Cells

PUB007 Novel TKIs in Non-Small Cell Lung Cancer

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

EGFR inhibitors and autophagy in cancer treatment

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?

Poly-therapy with EGFR, STAT3 and Src-YAP1 Signaling Pathway Inhibition; A Breakthrough for EGFR Mutant NSCLC

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment

Therapeutic Strategies in EGFR Mutant Non-Small Cell Lung Cancer

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy

Cross-Talk Between STYK1 and EGFR in Autophagy Regulation and EGFR-TKIs Sensitivity in Non-Small Cell Lung Cancer

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non–Small-Cell Lung Cancer Cells

Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers